Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Arch Toxicol ; 96(3): 783-792, 2022 03.
Artigo em Inglês | MEDLINE | ID: mdl-35072755

RESUMO

During chlorination treatments of drinking water, aqueous bisphenol A (BPA) can react with chlorine to form chlorinated derivatives of BPA (mono, di, tri and tetra-chlorinated derivatives) or ClxBPA. These emerging substances are endocrine disruptors associated with obesity, type II diabetes (TD2M) and myocardial infarction. ClxBPA are present in different human biological matrices but their toxicokinetics remain unknown. The aim of this study was to measure and compare the metabolic kinetics in the liver of four ClxBPA (ClBPA, Cl2BPA, Cl3BPA and Cl4BPA) between compounds and between species (Sprague-Dawley rats vs humans). To estimate their metabolic constants (Vmax, Km, Intrinsic clearance), metabolic assays were performed in hepatocyte suspensions. Assays revealed that metabolic constants of ClxBPA can greatly vary depending on substances and species. While ClBPA and Cl2BPA show similar unbound intrinsic clearances (ClintU) in rat incubation media, values for Cl3BPA and Cl4BPA are very different (3.109 and 0.684 mL/min/106 hepatocytes, respectively). Unlike in rats, human results are quite different as Cl3BPA and Cl4BPA have similar unbound intrinsic clearances, while ClBPA and Cl2BPA diverge (0.350 and 1.363 mL/min/106 hepatocytes, respectively). In both species, Cl2BPA and Cl3BPA have relatively similar clearances, and ClBPA is very different from Cl4BPA. Although we quantified the proportion of sulfo- and glucurono-metabolites, other metabolites may have been formed (e.g., glutathione, disulfate, or oxidative metabolites). This study showed that chlorination had an impact on hepatic intrinsic clearance of ClxBPA in rats and humans and measured values will be valuable for the development of PBPK models for use in exposure assessment.


Assuntos
Compostos Benzidrílicos/metabolismo , Disruptores Endócrinos/metabolismo , Hepatócitos/metabolismo , Fenóis/metabolismo , Adulto , Animais , Compostos Benzidrílicos/química , Disruptores Endócrinos/química , Halogenação , Humanos , Masculino , Fenóis/química , Ratos , Ratos Sprague-Dawley , Especificidade da Espécie
2.
Environ Int ; 153: 106547, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-33831741

RESUMO

CONTEXT: Bisphenol A (BPA) is a ubiquitous contaminant with endocrine-disrupting effects in mammals. During chlorination treatment of drinking water, aqueous BPA can react with chlorine to form chlorinated derivatives of BPA (mono, di, tri and tetra-chlorinated derivatives) or ClxBPA. OBJECTIVE: The aim of this study is to summarize and present the state of knowledge on human toxicological risk assessment of ClxBPA. MATERIALS AND METHODS: A search on ClxBPA in the PubMed database was performed based on studies published between 2002 and 2021. Forty-nine studies on chlorinated derivatives of BPA were found. Available information on their sources and levels of exposure, their effects, their possible mechanisms of action and their toxicokinetics data was extracted and presented. RESULTS: ClxBPA have been essentially detected in environmental aqueous media. There is evidence in toxicological and epidemiological studies that ClxBPA also have endocrine-disrupting capabilities. These emerging pollutants have been found in human urine, serum, breast milk, adipose and placental tissue and can constitute a risk to human health. However, in vitro and in vivo toxicokinetic data on ClxBPA are scarce and do not allow characterization of the disposition kinetics of these compounds. CONCLUSION: More research to assess their health risks, specifically in vulnerable populations, is needed. Some water chlorination processes are particularly hazardous, and it is important to evaluate their chlorination by-products from a public health perspective.


Assuntos
Poluentes Ambientais , Animais , Compostos Benzidrílicos/análise , Compostos Benzidrílicos/toxicidade , Cloro/toxicidade , Poluentes Ambientais/toxicidade , Feminino , Humanos , Fenóis , Placenta/química , Gravidez
3.
Ann Pharm Fr ; 78(4): 343-350, 2020 Jul.
Artigo em Francês | MEDLINE | ID: mdl-32253021

RESUMO

OBJECTIVES: The objective of this study was to quantify parabens intake due to drug administration in neonates during hospitalization following their birth. METHOD: A monocentric prospective study was performed into a neonatalogy unit to collect all drug prescriptions. An exhaustive list of parabens containing medicines commercialized in France was completed from Theriaque® database. This list was combined with drug prescription to establish an exposure profile to parabens. For each paraben containing medicines, a HPLC-UV assay was performed to determine the average daily intake of paraben received by hospitalized neonates. RESULTS: More than 300 medicines commercialized in France contain at least one paraben. A combination of methylparaben and propylparaben was found in most cases. All hospitalized neonates (n=22) were exposed at least once to methylparaben and propylparaben through medicines while 50 % were exposed to ethylparaben. The average daily intake was higher in term newborns (572,0±249,0 versus 414,6±294,1µg/kg/j for methylparaben) but frequency was higher in prematures (65,0 versus 78,6% for methylparaben) as well as cumutives doses (1421,5±758,8 versus 8618,7±7922,3). These doses are lower than toxicological reference values but these latter do not take into account endocrine disrupting effects of these compounds. CONCLUSIONS: These results highlight medicines as a high source of exposure to parabens in hospitalized neonates. It should encourage pharmaceutical companies and health professionnal to prioritize therapeutic cares without parabens.


Assuntos
Disruptores Endócrinos , Parabenos/efeitos adversos , Parabenos/análise , Conservantes Farmacêuticos/efeitos adversos , Conservantes Farmacêuticos/análise , Cromatografia Líquida de Alta Pressão , Composição de Medicamentos , França , Unidades Hospitalares , Hospitalização , Humanos , Recém-Nascido , Pacientes Internados , Neonatologia , Estudos Prospectivos
4.
Br J Dermatol ; 179(1): 101-109, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29150843

RESUMO

BACKGROUND: Psoriasis exhibits several extracutaneous manifestations. Little is known about hepatic parameters specifically associated with psoriasis. OBJECTIVES: To study whether psoriasiform dermatitis is associated with liver injury. METHODS: We studied liver parameters of inflammation and fibrosis in a murine model of psoriasiform dermatitis induced by topical application of imiquimod for 9 weeks. RESULTS: Topical treatment with imiquimod induced a form of psoriasiform dermatitis reminiscent of the human disorder, characterized by thickened and scaly skin, psoriasiform epidermal hyperplasia, altered keratinocyte differentiation and cutaneous overexpression of interleukin-17A. Mice with dermatitis displayed hepatitis, as shown by elevation of plasma transaminase levels, as well as portal and periportal hepatitis, characterized by T-lymphocyte (CD3ε+ ) and polymorphonuclear cell (Gr1+ ) infiltrates. The hepatitis progressed towards liver fibrogenesis, as shown by excessive Sirius red staining, which is consistent with the expression of α-smooth muscle actin by hepatic stellate cells. CONCLUSIONS: These results indicate that liver inflammation and fibrosis are associated with experimental psoriasiform dermatitis. Our results suggest that psoriatic inflammation may be associated with specific liver injury.


Assuntos
Toxidermias/etiologia , Imiquimode/toxicidade , Indutores de Interferon/toxicidade , Cirrose Hepática/etiologia , Psoríase/complicações , Animais , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Modelos Animais de Doenças , Imiquimode/administração & dosagem , Masculino , Camundongos Endogâmicos C57BL
5.
Talanta ; 125: 284-92, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24840445

RESUMO

Bisphenol A (BPA), a widespread man-made chemical classified as an endocrine disruptor, is increasingly considered as a major cause of concern for human health. Chlorine present in drinking water may react with BPA to form chlorinated derivatives (ClxBPA), which have demonstrated a heightened level of estrogenic activity. If many epidemiological studies report that more than 90% of people have detectable BPA levels in their urine, then no such study has been undertaken regarding ClxBPA. The purpose of this work is to propose a highly sensitive and accurate analytical method adapted to large-scale biomonitoring studies aimed at assessing exposure to BPA and ClxBPA through the use of human urine. To achieve this, we have comprehensively validated a method using salting-out assisted liquid/liquid extraction (SALLE) coupled to UPLC-MS/MS and isotope dilution quantification, to measure unconjugated BPA and ClxBPA in human urine according to the accepted guidelines. Deutered BPA as well as deutered 2,2'-DCBPA was used as internal standards. The matrix calibration curve ranged from 0.05 to 1.60 ng mL(-1) and from 0.5 to 16.0 ng mL(-1) for ClxBPA and BPA respectively, and provided good linearity (r²>0.99). This method was precise (the intra- and inter-day coefficients of variation were <20% at three different concentrations: 0.05 ng mL(-1), 0.2 ng mL(-1), 0.8 ng mL(-1) and 0.5 ng mL(-1), 2 ng mL(-1), 8 ng mL(-1) for ClxBPA and BPA, respectively) and accurate (bias ranged from -13% to +12%). The limit of quantification, validated at 0.05 ng mL(-1) and 0.5 ng mL(-1) for ClxBPA and BPA respectively when using 300 µL of urine, was found to be suitable for the concentration existing in real samples. The matrix effect and the BPA cross-contamination were also investigated in this study. The analytical method developed in this study is in accordance with the requirements applicable to biomonitoring of BPA and ClxBPA in human urine.


Assuntos
Compostos Benzidrílicos/urina , Cloro/análise , Cromatografia Líquida de Alta Pressão , Fenóis/urina , Espectrometria de Massas em Tandem , Urinálise/normas , Urina/química , Calibragem , Técnicas de Química Analítica , Humanos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade
6.
Med Mal Infect ; 42(9): 421-8, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22938775

RESUMO

OBJECTIVE: The authors had for aim to describe the effectiveness and the safety of a saquinavir/ritonavir (SQV/r) regimen, 1000/100mg twice daily, in HIV-infected pregnant patients. PATIENTS AND METHOD: We made a prospective and observational study of HIV positive female patients beginning or going on SQV/r antiretroviral treatment (ART) during pregnancy. RESULTS: Sixty-two patients were enrolled from July 2007 to June 2009 in 10 infectious diseases units in France. Thirty-six women (group 1) were ART naive on inclusion, 20 (group 2) had been previously treated and then switched to SQV/r, six (group 3) were treated with SQV/r before pregnancy. 58 patients delivered while on SQV/r regimen after a median pregnancy duration of 39 WA. Eighty percent had a viral load below 50 copies/mL and 93% below 400 copies/mL: respectively 77% and 93.5% in group 1, 83% and 89% in group 2, 83% and 100% in group 3. The median SQV minimum concentrations (C(min)) measured at the third trimester and at delivery were adequate, respectively 0.91 mg/L and 0.86 mg/L. Most women (52%) had a vaginal delivery; 12 (21%) had an elective caesarean section, for obstetrics factors in eight cases. None of the newborns were HIV-infected at 6 months of age (n = 59, one death at day 3). Only one severe adverse event occurred due to saquinavir (maternal grade 3 hepatotoxicity). CONCLUSION: SQV/r 1000/100mg twice daily seems to be effective and safe in HIV-infected pregnant women with adequate saquinavir C(min).


Assuntos
Infecções por HIV/tratamento farmacológico , Inibidores da Protease de HIV/uso terapêutico , HIV-1 , HIV-2 , Complicações Infecciosas na Gravidez/tratamento farmacológico , Ritonavir/uso terapêutico , Saquinavir/uso terapêutico , Adulto , Contagem de Linfócito CD4 , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Estudos de Coortes , Parto Obstétrico/estatística & dados numéricos , Quimioterapia Combinada , Feminino , Infecções por HIV/congênito , Infecções por HIV/prevenção & controle , Infecções por HIV/transmissão , Inibidores da Protease de HIV/administração & dosagem , Inibidores da Protease de HIV/efeitos adversos , Humanos , Recém-Nascido , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Masculino , Gravidez , Resultado da Gravidez , Estudos Prospectivos , Ritonavir/administração & dosagem , Ritonavir/efeitos adversos , Saquinavir/administração & dosagem , Saquinavir/efeitos adversos , Resultado do Tratamento , Carga Viral , Viremia/tratamento farmacológico , Adulto Jovem , Zidovudina/administração & dosagem , Zidovudina/uso terapêutico
7.
Pharmacol Res ; 61(2): 167-74, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19800973

RESUMO

The aim of this study was to analyze retrospectively and critically the different steps of the individual dose adjustment procedure employed in the concentration-controlled (CC) versus fixed-dose trial Apomygre, which showed that mycophenolate mofetil (MMF) dose adjustment using a limited sampling strategy significantly reduced the risk of treatment failures and acute rejection in renal transplants at one year posttransplantation. The number of AUCs performed during the study and circumstances of collection, time of blood sampling, Bayesian mycophenolic acid (MPA) area-under-the-curve (AUC) estimation procedures and physicians' compliance with MMF dose recommendations were retrospectively analyzed. 92% of AUCs scheduled over the study were actually performed. Sampling times were very well respected. Bayesian estimation of MPA exposure was done by the pharmacologists locally in accordance with the protocol instructions and the AUC estimates obtained were virtually all confirmed a posteriori. On the other hand, a second AUC estimated by multiple linear regression could only be provided for 84% of the profiles and showed a large overestimation with respect to Bayesian estimates for AUC values between 10 and 55mgh/L. In the CC arm, a very good physicians' compliance was observed (85%) and application of the dose recommendations led to higher values of AUCs (42.1+/-14.6mgh/L versus 36.7+/-16.3mgh/L, p=0.0035) and to more AUCs in the target range (69% versus 56%, p=0.0343) than when dose recommendations were not applied. By analyzing in detail the feasibility criteria of MMF Bayesian dose adjustment, this study highlighted the requirements for successful extrapolation of the Apomygre trial results to routine practice: (i) respect of the PK sampling time-windows; (ii) use of relevant tools for accurate drug exposure estimation and dose adjustment calculation; and (iii) good compliance of the physicians with regard to the recommended doses.


Assuntos
Teorema de Bayes , Cálculos da Dosagem de Medicamento , Monitoramento de Medicamentos/métodos , Rejeição de Enxerto/prevenção & controle , Imunossupressores/administração & dosagem , Transplante de Rim , Ácido Micofenólico/análogos & derivados , Ensaios Clínicos Controlados Aleatórios como Assunto , Doença Aguda , Área Sob a Curva , Relação Dose-Resposta a Droga , Estudos de Viabilidade , França , Rejeição de Enxerto/etiologia , Sobrevivência de Enxerto/efeitos dos fármacos , Fidelidade a Diretrizes , Humanos , Imunossupressores/sangue , Transplante de Rim/efeitos adversos , Modelos Lineares , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/sangue , Guias de Prática Clínica como Assunto , Padrões de Prática Médica , Estudos Retrospectivos , Fatores de Tempo , Resultado do Tratamento
8.
Int J Sports Med ; 27(3): 187-92, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16541373

RESUMO

We aimed to assess the plasma and urine concentrations of beta2-agonists and evaluate the difference between three routes of administration in trained adults in order to distinguish doping from prevention of exercise-induced asthma. Ten young healthy Caucasian male subjects received during a four treatment period study: 1) inhaled salbutamol (S(I)) 2 x 100 microg t.i.d. for 3 days, 2) inhaled formoterol (F(I)) 2 x 12 microg b.i.d. for 3 days, 3) a single subcutaneous injection of salbutamol (S(S)) 0.5 mg, and 4) salbutamol 2 x 2 mg t.i.d. orally for 3 days (S(O)). Blood samples were taken during the first and the third day of experimentation at baseline, 30 min, 1 h, 2 h, 4 h and 6 h after administration; additional blood samples were drawn at 15 min for S(I), S(S) and F(I) and at 12 h for F(I). Urinary samples were collected at baseline, 2 h, 4 h, 6 h and 12 h after administration. Urinary concentrations were 20 to almost 50 times higher after S(O) than after S(I). Mean urinary concentration after S(O) increased to above 800 ng.mL(-1) within the two hours and above 1000 ng.mL(-1) at 6 to 12 hours post-drug administration. Urinary concentrations after S(S) were maximal during the first 2 hours (mean: 340 +/- 172 ng.mL(-1)). Plasma concentrations were very low, whatever the routes of administration. Results showed that we could eliminate the use of S(I) (authorized) and S(S) administration when individual urinary concentrations are higher than 230 ng.mL(-1) and 615 ng.mL(-1), respectively. Therefore, at rest, the cut-off value used to discriminate therapeutic from doping salbutamol intake could be fixed at 250 ng.mL(-1) instead of the 1000 ng.mL(-1) still authorized by international committees.


Assuntos
Agonistas Adrenérgicos beta/administração & dosagem , Albuterol/administração & dosagem , Dopagem Esportivo , Administração por Inalação , Administração Oral , Agonistas Adrenérgicos beta/sangue , Agonistas Adrenérgicos beta/urina , Adulto , Albuterol/sangue , Albuterol/urina , Análise de Variância , Humanos , Injeções , Masculino
9.
Intensive Care Med ; 29(9): 1528-34, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12856119

RESUMO

OBJECTIVE: To compare the pharmacokinetic parameters of sequential intravenous and subcutaneous teicoplanin in the plasma of surgical intensive care unit patients. DESIGN AND SETTING: Prospective, randomized, crossover study in the surgical ICU of a university hospital. PATIENTS: Twelve patients with a suspected nosocomial infection, a serum albumin level higher than 10 g/l, body mass index less than 28 kg/m(2), and estimated creatinine clearance higher than 70 ml/min. INTERVENTIONS: Teicoplanin was first administered intravenously as a loading dose of 6 mg/kg per 12 h for 48 h and then continued at a daily dose of 6 mg/kg. On the fourth day patients were randomized in two groups according to the order of the pharmacokinetic studies. MEASUREMENTS AND RESULTS: Serial plasma samples were obtained to measure teicoplanin levels. Compared with a 30-min intravenous infusion the peak concentration of teicoplanin after a 30-min subcutaneous administration occurred later (median 7 h, range 5-18) and was lower (16 micro g/ml, 9-31; vs. 73, 53-106). Despite large and unpredictable interindividual differences no significant differences between subcutaneous and intravenous administration were observed in: trough antibiotic concentrations (10 micro g/ml, 6-24; vs. 9, 5-30), the area under the teicoplanin plasma concentration vs. time curves from 0 to 24 h (AUC(0-24h); 309 micro g/ml per minute, 180-640; vs. 369, 171-955), the proportion of the dosing interval during which the plasma teicoplanin concentration exceeded 10 micro g/ml (96%, 0-100%; vs. 79%, 13-100%), and the ratio of AUC(0-24h) to 10 (77, 45-160; vs. 92, 43-239). CONCLUSIONS: In critically ill patients without vasopressors a switch to the subcutaneous teicoplanin after an initial intravenous therapy seems to give comparable pharmacodynamic indexes of therapeutic success.


Assuntos
Antibacterianos/administração & dosagem , Infecção Hospitalar/tratamento farmacológico , Teicoplanina/administração & dosagem , Adolescente , Adulto , Idoso , Albuminas/análise , Antibacterianos/sangue , Antibacterianos/farmacocinética , Área Sob a Curva , Estado Terminal , Infecção Hospitalar/sangue , Estudos Cross-Over , Feminino , Humanos , Infusões Intravenosas , Infusões Parenterais/métodos , Injeções Subcutâneas/métodos , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Estudos Prospectivos , Teicoplanina/sangue , Teicoplanina/farmacocinética , Resultado do Tratamento , Vasoconstritores
10.
J Anal Toxicol ; 27(1): 7-14, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12587676

RESUMO

A complete general unknown screening procedure was developed using liquid chromatography-mass spectrometry (LC-MS), a coupling that can increase the range of compounds amenable to MS. Sample preparation was by solid-phase extraction on a mixed-mode support in parallel with serum deproteination in order to recover the most hydrophilic compounds. Chromatography employed a reversed-phase narrow-bore column (150 x 1-mm i.d.) and a 50-min gradient elution at low flow-rate (50 microL/min), compatible with the electrospray source used without splitting nor heating. The single quadrupole LC-MS instrument used was operated in the 100 to 1100 mu mass range in both the positive and negative modes, with two different, alternated collision-induced dissociation voltages in the source, in order to obtain the molecular or pseudo-molecular ions as well as fragments for the compounds analyzed. The addition of spectra obtained at low and high fragmentation voltages gave reconstructed spectra for each polarity, representing library entries. Finally, a program was created in order to detect the peaks of interest in the chromatographic noise using a very efficient signal processing algorithm, compute their relative retention time with respect to the internal standard (glafenine), draw their reconstructed spectra, search them in the libraries, and edit a report.


Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Programas de Rastreamento/métodos , Preparações Farmacêuticas/sangue , Espectrometria de Massas por Ionização por Electrospray/métodos , Xenobióticos/sangue , Humanos , Preparações Farmacêuticas/análise , Xenobióticos/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...